GLOBAL MOLECULAR GENETIC TESTING FOR AUTOIMMUNE DISEASES MARKET (2024 - 2030)

The Global Molecular Genetic Testing for Autoimmune Diseases Market was valued at USD 700 million and is projected to reach a market size of USD 984.97 million by the end of 2030. Over the forecast period of 2024–2030, the market is projected to grow at a CAGR of 5%.

Molecular genetic testing is a subset of genetic testing that examines the composition and arrangement of human genes in a lab setting. For autoimmune illnesses, molecular genetic testing can be used to both identify and forecast the likelihood of having an autoimmune disease. In the past, this market had a limited presence because of its limited database, knowledge, and tools. Presently, this market has achieved a notable boost owing to technological advancements, R&D activities, and increased initiatives. In the future, with a growing focus on personalized medicine, expanded testing facilities, and rising investments, this market will experience good growth.

 Key Market Insights:

Approximately 2.2 million genetic tests were conducted globally in 2022 to employ precision medicine for medical treatments. This number is expected to rise to around 5.5 million by 2027.

Approximately 11.6 billion US dollars were allocated to the NIH for genetics for the fiscal year 2022.

PCR is predicted to hold a 43.3 percent market share in molecular diagnostics by 2031.

By 2030, the global market for diagnostics for autoimmune diseases is expected to be valued at $9.98 billion.

More than half of the population, out of 8.1 billion people, lacks access to basic healthcare facilities. To tackle this, measures are being taken by institutes, organizations, and governmental bodies through investments and awareness programs. Besides, strategies are being created to reduce the cost of healthcare expenses.

Molecular Genetic Testing for Autoimmune Diseases Market Drivers:

An increasing prevalence of diseases has been fueling market growth.

Over the years, numerous changes have been observed in the standard of living and consumer preferences. This includes alterations in diets, exposure to harmful radiation, and other environmental factors. A few autoimmune diseases like multiple sclerosis, rheumatoid arthritis, type 1 diabetes, Crohn's disease, psoriasis, and lupus have seen an upsurge in incidence due to these variations. Besides, genetic alterations have been contributing to this. Autoimmune disorders cannot be cured but controlled. Therefore, there has been a significant rise in awareness through various modes and platforms. Social media has been playing a huge role in highlighting the warning signs, treatments, awareness month, symptoms, etc. Secondly, educational campaigns and training programs are being conducted to shed light on these issues. Furthermore, quarterly checkups are being encouraged for prevention and diagnosis.

Technological advancements have been accelerating the expansion.

Bioinformatics has played a vital role in gathering and generating many databases to broaden human understanding. This data is used for the prediction of genetic diseases right from the fetal stage itself. Various tools are available in this category to aid in sequencing. Additionally, integration with artificial intelligence and machine learning technologies has improved the accuracy of the diagnostics. Secondly, next-generation sequencing (NGS) helps with the rapid sequencing of genomes to generate thousands of base pairs of DNA, RNA, and mutant variation. Thirdly, biological molecules in complex samples can be identified and quantified using omics methods. These tools can be used to describe an organism's dynamics, structure, and function. Moreover, other advancements like single-cell sequencing, CRISPR, and genome editing have been a boon. Furthermore, research activities are being prioritized through various funding and collaborations.

Molecular Genetic Testing for Autoimmune Diseases Market Restraints and Challenges:

Associated costs, data security, limited comprehension, a lack of trained professionals, and unequal access are the main issues that the market is currently experiencing.

Affordability is one of the biggest barriers in this market. The equipment and diagnostic tools that are used require upgrades and proper maintenance. These charges can financially drain smaller firms. Secondly, the privacy of data is another concern. Sensitive information regarding the patient's clinical records and other genetic data can be leaked or misused. This can result in huge financial losses and create threats to mankind by creating harmful viruses or other toxins. Thirdly, there is a limited understanding as well as data availability in the genetics field. This can lead to complexity in interpretation. Moreover, obstacles can be faced while integrating the data because there is an inadequacy of people with expertise. Furthermore, a few remote and underdeveloped areas might not have equal access to various resources and infrastructure.

Molecular Genetic Testing for Autoimmune Diseases Market Opportunities:

The concept of personalized medicine has provided the market with an infinite number of possibilities. This involves making medications and drugs as per the genetic makeup of an individual. Biomarkers are used for this purpose. This is a great advantage, as it helps in early detection and diagnosis. Secondly, R&D activities have been undergoing significant milestones in developing novel biomarkers, proteins, and the exact genetic variation that leads to disease creation. Thirdly, integration with healthcare facilities has been helping with patient engagement and awareness. The market is seeing an augmentation through global operations, data sharing, publications, and other part

GLOBAL MOLECULAR GENETIC TESTING FOR AUTOIMMUNE DISEASES  MARKET REPORT COVERAGE:

Molecular Genetic Testing for Autoimmune Diseases Market Segmentation:

Market Segmentation: By Disease Type:

• Rheumatoid Arthritis (RA)
• Systemic Lupus Erythematosus (SLE)
• Type 1 Diabetes
• Multiple Sclerosis (MS)
• Inflammatory Bowel Disease (IBD)
• Others

Rheumatoid arthritis (RA) is the largest disease type in this market. One of the major reasons for this is the number of cases that have been registered and estimated over the forecast period. According to recent estimates, more than 350 million people are diagnosed with this condition, thereby creating a crucial need for testing. Type 1 diabetes is one of the fastest-growing disease types. The immune system of the body targets and kills the beta cells in the pancreas that produce insulin, resulting in type 1 diabetes. 8.75 million people globally will suffer from type 1 diabetes in 2022. This has raised the need for testing to help in controlling and managing this disease.

Market Segmentation: By Technology:

• Polymerase Chain Reaction (PCR)
• Microarray
• Next-Generation Sequencing (NGS)
• In Situ Hybridization
• Others

Based on technology, PCR is the largest segment. This very sensitive and precise technique can be used to identify and measure certain nucleic acids in a clinical sample. Its use enables the very sensitive, accurate, and quick diagnosis and treatment of autoimmune illnesses. Besides, it can be used to detect diseases even with a small sample amount. NGS is the fastest-growing method. NGS can identify mutations and variations in both DNA and RNA. In a short amount of time, it may sequence thousands of genes or a whole genome.

Market Segmentation: By End-Users:

• Hospitals and Clinics
• Diagnostic Centers
• Pharmaceutical and Biotechnology Companies
• Research Institutes
• Others

Based on end-users, hospitals and clinics are the largest in the market. This is because these channels are equipped with advanced resources and infrastructure, which is necessary for testing. Besides, licensed professionals are present who perform accurate testing and other procedures. This increases the trust of patients. Apart from this, to keep up with the upgrades and maintain the available facilities, they are financed regularly by business tycoons, multinational companies, and other governmental bodies. Diagnostic centers are considered to be the fastest-growing segment. The success of this segment is mainly because of their affordability when compared to bigger organizations. Several improvements have been made to improve the available equipment by funding these institutes. Besides, greater work opportunities are being provided in these centers, thereby attracting more individuals to join these places.

Market Segmentation: Regional Analysis:

• North America
• Asia-Pacific
• Europe
• South America
• Middle East and Africa

Based on region, North America is the largest segment, holding a rough share of 30%. The most dominant countries in this region include the United States and Canada. This area is well-equipped with advanced healthcare systems. These channels have technologies and diagnostic testing facilities that aid growth. Secondly, this region has prestigious research institutes that have experienced many breakthroughs because of the presence of renowned scholars. Universities like Johns Hopkins, Harvard, and the Massachusetts Institute of Technology are the most prominent ones. Apart from this, major players are present in this region who have good funds, collaborations, and global operations in this market. Asia-Pacific is the fastest-growing region with countries like Singapore, India, China, and Japan being the notable ones. This region holds an approximate share of 22%. These regions have a growing healthcare system. Funds are being increased as the economy becomes more stable. This includes rapid advancements in diagnostic facilities. Several research institutes have been witnessing progress by focusing on partnerships, advanced research, and technologies that generate more precise and accurate results. Furthermore, an increasing incidence of autoimmune diseases has put a greater emphasis on awareness and genetic testing methods.

COVID-19 Impact Analysis on the Global Molecular Genetic Testing for Autoimmune Diseases Market:

The outbreak of the virus had a positive impact on the market. Most of the funding was shifted towards healthcare applications. This included research activities as a prominent category. Several prestigious institutes and universities were working towards deepening human knowledge. Studies were carried out to determine if there was any increased risk for autoimmune diseases in patients who were affected by the coronavirus. According to a paper by Nature Journal, compared to a non-COVID-19 cohort of 1,560,357 people who were matched for age, sex, and whether or not they had a prior autoimmune illness, the researchers found that there was a 42.6% increased chance of developing an autoimmune ailment 3–15 months after infection. Besides, variations in genes for people who had autoimmune diseases and were affected by the virus were also studied. Many bioinformatics tools and other computational techniques have gained attention. Post-pandemic, the market has continued to grow owing to increased investments and partnerships.

Latest Trends/ Developments:

The safety of data is being prioritized through various software, encryption methods, authenticity testing, and other measures. Fields like AI have been facilitating pattern detection, analysis, and response. Apart from this, data masking and access control are being given utmost prominence. Other fields like IoT, ML, behavioral biometrics, and blockchain technologies are being explored to enhance security.

Key Players:

• Abbott Laboratories
• Thermo Fisher Scientific
• Illumina
• Bio-Rad Laboratories
• Roche Diagnostics
• Acacia Research
• Qiagen
• PerkinElmer
• Eurofins Scientific
• Myriad Genetics

In October 2023, the immune system's memory of a single molecule was eliminated by the novel vaccination created by US researchers at the Pritzker School of Molecular Engineering (PME) at the University of Chicago. A novel kind of inverse vaccine has been demonstrated in a laboratory environment to fully correct autoimmune illnesses, including type 1 diabetes and multiple sclerosis, all without impairing the immune system as a whole.

In September 2023, Verily and Kyverna Therapeutics collaborated to find new biomarkers and develop innovative approaches for designing and carrying out clinical trials for autoimmune diseases like lupus. Through multi-year cooperation, cell therapy engineering and precision health technologies will be combined to better understand the biology underlying the immune system's reset by CAR-T cell therapy.

In February 2023, Roche and Janssen Biotech extended their partnership to encompass a broad spectrum of companion diagnostics, such as tissue and blood-based biomarkers, sequencing, digital pathology, next-generation sequencing, polymerase chain reaction, and immunoassays. In addition, possible cooperation in the precision medicine area is covered by the enlarged agreement. This includes the use of immunohistochemistry (IHC) testing to identify patients who have certain disease markers.